Wild-type (senile) amyloidosis pathophysiology: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Wild-type (senile) amyloidosis}} | {{Wild-type (senile) amyloidosis}} | ||
{{CMG}}{{AE}}{{ | {{CMG}}{{AE}}{{Sab}} | ||
==Overview== | ==Overview== | ||
==Pathophysiology== | ==Pathophysiology== | ||
*[[Amyloid]] is an abnormal insoluble [[extracellular]] [[protein]] that deposits in the different tissues and causes organic dysfunction and a wide variety of clinical syndromes.<ref name="pmid26719234">{{cite journal |vauthors=Wechalekar AD, Gillmore JD, Hawkins PN |title=Systemic amyloidosis |journal=Lancet |volume=387 |issue=10038 |pages=2641–2654 |date=June 2016 |pmid=26719234 |doi=10.1016/S0140-6736(15)01274-X |url=}}</ref> | |||
*These abnormal [[Amyloid|amyloids]] are derived from misfolding and aggregation of normally soluble [[Protein|proteins]]. | |||
*[[Amyloid]] deposition can disrupt tissue structure of involved organ and consequently leads to organ failure.<ref name="pmid267192342">{{cite journal |vauthors=Wechalekar AD, Gillmore JD, Hawkins PN |title=Systemic amyloidosis |journal=Lancet |volume=387 |issue=10038 |pages=2641–2654 |date=June 2016 |pmid=26719234 |doi=10.1016/S0140-6736(15)01274-X |url=}}</ref> | |||
===Systemic Amyloidosis=== | |||
*In systemic amyloidosis, [[amyloid]] gradually accumulates and [[amyloid]] deposition is widespread in the viscera, [[blood vessel]] walls, and different [[Connective tissue|connective tissues]].<ref name="pmid23227278">{{cite journal |vauthors=Baker KR, Rice L |title=The amyloidoses: clinical features, diagnosis and treatment |journal=Methodist Debakey Cardiovasc J |volume=8 |issue=3 |pages=3–7 |date=2012 |pmid=23227278 |pmc=3487569 |doi= |url=}}</ref><ref name="pmid16409147">{{cite journal |vauthors=Pepys MB |title=Amyloidosis |journal=Annu. Rev. Med. |volume=57 |issue= |pages=223–41 |date=2006 |pmid=16409147 |doi=10.1146/annurev.med.57.121304.131243 |url=}}</ref> | |||
===Pathogenesis=== | ===Pathogenesis=== | ||
* Wild-type (senile) amyloidosis is a type of systemic amyloidosis. | * Wild-type (senile) amyloidosis is a type of systemic amyloidosis. | ||
* The culprit protein responsible for the disease is transthyretin (TTR) and it is deposited in the non-mutated form, hence the name "Wild-type". | * The culprit protein responsible for the disease is transthyretin (TTR) and it is deposited in the non-mutated form, hence the name "Wild-type". | ||
Revision as of 16:10, 17 December 2019
|
Wild-type (senile) amyloidosis Microchapters |
|
Differentiating Wild-type (senile) amyloidosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Wild-type (senile) amyloidosis pathophysiology On the Web |
|
American Roentgen Ray Society Images of Wild-type (senile) amyloidosis pathophysiology |
|
Risk calculators and risk factors for Wild-type (senile) amyloidosis pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]
Overview
Pathophysiology
- Amyloid is an abnormal insoluble extracellular protein that deposits in the different tissues and causes organic dysfunction and a wide variety of clinical syndromes.[1]
- These abnormal amyloids are derived from misfolding and aggregation of normally soluble proteins.
- Amyloid deposition can disrupt tissue structure of involved organ and consequently leads to organ failure.[2]
Systemic Amyloidosis
- In systemic amyloidosis, amyloid gradually accumulates and amyloid deposition is widespread in the viscera, blood vessel walls, and different connective tissues.[3][4]
Pathogenesis
- Wild-type (senile) amyloidosis is a type of systemic amyloidosis.
- The culprit protein responsible for the disease is transthyretin (TTR) and it is deposited in the non-mutated form, hence the name "Wild-type".
- The normal TTR protein compared with the mutated form is less likely to get deposited and to cause a pathology
References
- ↑ Wechalekar AD, Gillmore JD, Hawkins PN (June 2016). "Systemic amyloidosis". Lancet. 387 (10038): 2641–2654. doi:10.1016/S0140-6736(15)01274-X. PMID 26719234.
- ↑ Wechalekar AD, Gillmore JD, Hawkins PN (June 2016). "Systemic amyloidosis". Lancet. 387 (10038): 2641–2654. doi:10.1016/S0140-6736(15)01274-X. PMID 26719234.
- ↑ Baker KR, Rice L (2012). "The amyloidoses: clinical features, diagnosis and treatment". Methodist Debakey Cardiovasc J. 8 (3): 3–7. PMC 3487569. PMID 23227278.
- ↑ Pepys MB (2006). "Amyloidosis". Annu. Rev. Med. 57: 223–41. doi:10.1146/annurev.med.57.121304.131243. PMID 16409147.